#USA #Fort Myers #precision dosing #Baysient #iDose

Baysient Unveils iDose® GEN7.0 for Inflammatory Diseases

Baysient, a frontrunner in the precision medicine field, has recently announced the launch of its latest innovation, iDose® GEN7.0. This cutting-edge platform expands the capacity of its FDA-regulated dosing decision support system to now include a total of 17 inflammatory disease indications. With this new version, medical professionals can utilize pharmacokinetic-informed therapeutic drug monitoring (TDM) specifically for conditions such as inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, and psoriasis. The goal is to empower clinicians to optimize biologic therapies with unprecedented accuracy.

The innovative iDose GEN7.0 integrates three powerful predictive decision support tools, effectively shifting treatment monitoring from a reactive to a proactive approach. These tools offer real-time probabilities related to the occurrence of anti-drug-antibodies, normalization of C-reactive protein (CRP), and mucosal healing. By harnessing these capabilities, physicians across diverse specialties can better identify patients who may require dose adjustments and meticulous clinical oversight to avoid treatment failures and enhance therapeutic outcomes.

Baysient’s commitment to advancing precision dosing is evident in the improved workflow it presents, as the platform features enhanced numerical entry capabilities and is fully ready for integration with Electronic Health Records (EHR) and Electronic Medical Records (EMR). This enhancement simplifies the incorporation of precision dosing into the daily routines of healthcare providers.

Baysient's approach combines intelligent technology with fundamental pharmacokinetic science, ensuring personalized dosing decisions for biologic treatments, tailored to the unique requirements of individual patients.

Healthcare professionals interested in learning more about the capabilities of iDose GEN7.0 can visit baysient.net/idose-product/ for detailed information or request a demonstration through baysient.net/demo/.

Regulatory Information

The iDose platform is regulated by the FDA under section 520 (o) of the Federal Food, Drug, and Cosmetic Act, functioning as decision support software. It is available as a software service intended for use by health care professionals who are not economically motivated regarding drug product distribution. For firms with such economic motivations, enterprise licensing is available. Regulatory guidance from the FDA has also been published to outline the requirements applicable to firms engaged with iDose.

About Baysient

Baysient specializes in developing cloud-based Software as a Service (SaaS) platforms, providing a comprehensive array of individual dosage-determination instruments for medical practitioners. The software leverages patients' routine lab results and demographic data, enabling physicians to customize dosing to achieve specific therapeutic targets effectively. For further insights about Baysient and its products, please visit baysient.net.